Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial.

Area of Science:

• Oncology
• Pharmacokinetics
• Clinical Pharmacology

Background:

• Pemetrexed is a key chemotherapy for non-small cell lung cancer and mesothelioma.
• Optimizing pemetrexed dosing by renal function, rather than body surface area (BSA), may reduce variability and improve outcomes.

Purpose of the Study:

• To compare optimized renal function-based pemetrexed dosing against standard BSA-based dosing.
• To evaluate the impact on pharmacokinetic variability and treatment efficacy.

Main Methods:

• A multicenter randomized controlled trial (1:1 ratio) included 81 patients eligible for pemetrexed chemotherapy.
• Area under the concentration-time curve (AUC) was measured to determine pemetrexed exposure.
• The proportion of patients achieving a target AUC (164 mg×h/L ± 25%) was compared between groups.

Main Results:

• No statistically significant difference in target AUC attainment between optimized (89%) and BSA-based (84%) dosing arms (p=0.505).
• Mean pemetrexed AUC was similar in both groups: 155 mg×h/L (optimized) vs. 160 mg×h/L (standard) (p=0.436).

Conclusions:

• Optimized pemetrexed dosing based on renal function did not demonstrate superiority over standard BSA-based dosing.
• No added benefit was observed for pharmacokinetic endpoints, safety, or quality of life (QoL) in patients with adequate renal function.